The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Cooper Companies (COO) Gets Buy Rating From William Blair Following Q2 Report

Analyst upgrade Earnings report AI-generated analysis

πŸ“ˆ William Blair analyst Margaret Kaczor upgraded Cooper Companies (COO) to a Buy rating following strong fiscal Q2 2025 results released on May 29.

πŸ’° The company reported $1.002 billion in revenue, representing a 6% year-over-year increase compared to the prior period.

πŸ“Š Non-GAAP diluted earnings per share reached $0.96, marking a 14% increase from the same quarter last year.

πŸš€ Management raised its fiscal year 2025 revenue guidance to a range of $4.107 billion to $4.146 billion.

πŸ“ˆ The company projects organic revenue growth of 5% to 6% for the upcoming fiscal year.

βš™οΈ Strong operating leverage from internal investments is driving the improved financial performance and margin expansion.

πŸ”¬ Cooper Companies operates through two segments: Cooper Surgical focusing on women's health and Cooper Vision addressing various vision challenges.

🌍 Strategic initiatives include product launch acceleration, production capacity expansion, and geographical expansion to support growth.

πŸ’‘ Analysts view the company as poised for durable mid- to high-single-digit growth supported by its strategic positioning.

Bullish Signals
  • William Blair analyst Margaret Kaczor upgraded Cooper Companies (COO) to a Buy rating following strong fiscal Q2 2025 results.
  • The company exceeded expectations with revenue growing 6% year-over-year to $1.002 billion in the second quarter of fiscal 2025.
  • Non-GAAP diluted earnings per share increased 14% to $0.96, demonstrating strong profitability and operational efficiency.
  • Management raised its full-year fiscal 2025 revenue guidance to a range of $4.107 billion to $4.146 billion.
  • The company projects organic revenue growth of 5% to 6% for fiscal year 2025, indicating sustainable business expansion.
  • Strong operating leverage from internal investments is driving improved financial performance and margin expansion.
  • Strategic initiatives including product launch acceleration and production capacity expansion support durable mid- to high-single-digit growth.
Full Analysis
William Blair analyst Margaret Kaczor upgraded Cooper Companies, Inc. (NASDAQ: COO) to a Buy rating following the release of its fiscal Q2 2025 results on May 29. The company exceeded market expectations with revenue growing 6% year-over-year to $1.002 billion and non-GAAP diluted EPS rising 14% to $0.96, driven by operating leverage from internal investments. The analyst highlighted that the strong financial performance prompted management to raise its earnings guidance for fiscal year 2025, projecting total revenue between $4.107 billion and $4.146 billion. This represents an organic growth rate of 5% to 6%, signaling confidence in the company's ability to sustain robust mid- to high-single-digit growth through strategic initiatives. Cooper Companies operates through two main segments: Cooper Surgical, which focuses on women's health and fertility products, and Cooper Vision, which develops medical devices for vision challenges. The analyst believes these strategic areas, including product launch acceleration and production capacity expansion, will support the company's durable growth trajectory despite conservative market expectations.